PEACE-3 Study Results: Study Population & Disposition

An expert discusses the design and objectives of the Phase 3 PEACE-3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) for ARPI-naïve metastatic castration-resistant prostate cancer (mCRPC).

EP: 1.Case presentation: Patient with metastatic CRPC after ARPI and docetaxel for localized PC

EP: 2.Therapeutic options for a patient with mCRPC after ADT + docetaxel

EP: 3.PEACE-3 study of enzalutamide + Ra-223 for ARPI-naïve mCRPC: Design and objectives

Now Viewing

EP: 4.PEACE-3 Study Results: Study Population & Disposition

Please review the design and objectives of the phase 3 PEACE 3 study of ENZA + Ra-223 for ARPI-naïve mCRPC.

Recent Videos